Introduction
Alzheimer's disease (AD) is now recognized as a major public health problem that has devastating effects on both the patients and their families. It is characterized by gradual loss of cognition that results in functional decline, behavioural and psychological problems and loss of quality of life. Loss of central cholinergic function in the brain of patients with AD, associated with substantial loss of cholinergic neurons in the nucleus basalis and loss of choline acetyl transferase, first in the entorhinal cortex and then in the hippocampus and other areas of neocortex, 1 has been correlated with deficits in memory and other aspects of cognition. 2 A number of approaches have been investigated to enhance cholinergic transmission in AD. To date, however, acetylcholinesterase inhibitors (AChE-Is) are the only cholinergic agents demonstrating efficacy versus placebo in treating the symptoms of this disease. 3 It is well known that the primary action of AChE-Is is to M Tsolaki, T Pantazi, A Kazis Acetylcholinesterase inhibitors versus nootropics enhance intrasynaptic acetylcholine by inhibiting breakdown of released acetylcholine. Some randomized, double-blind, placebocontrolled studies have shown that AChE-Is, such as tacrine (Cognex), 4 donepezil (Aricept) 5 and rivastigmine (Exelon), 6 have significant benefit on measures of cognition and Clinician's Interview-Based Assessment of Change-Plus (CIBIC-P) and Activities of Daily Living (ADL), whereas other pooled study analyses showed either no significant effect 7 or only a modest improvement in cognitive function compared with placebo. 8, 9 There is, however, some evidence that they stabilize symptoms and improve psychological function, behavioural difficulties and functional ability in some patients. 10 Although there is evidence that AChE-Is are significantly more effective in the treatment of AD than placebo, 8, 9 there is no evidence that AChE-Is have any significant advantage compared with other, older types of medication, such as nootropics and anti-inflammatory and cardiovascular drugs.
Nimodipine, a dihydropyridine calcium antagonist, has been reported to have beneficial effects in the treatment of senile dementias, acute ischaemic infarction and 'organic brain syndromes' (as characterized by diminished sensitivity to exogenous stimuli or decreased sleep, motor activity, mental alertness and memory performance). This agent is capable of enhancing cholinergic tone, neurofilament/ microtubular stabilization and regional perfusion rates. 11 In recent years, the dihydropyridine calcium antagonists have been the subject of investigation for treatment of cerebrovascular disease 12 and dementia. 13 It is now well known that other neurons, in addition to cholinergic neurons, are affected in AD. Ergot derivatives can interact with all monoamine systems by binding to the specific receptors for noradrenaline, dopamine and serotonin. 14 Moreover, the role of dopamine receptor stimulation has been stressed in the evaluation of ergot derivatives active on ageing brain symptoms. 15 One of the most important is the well-known hydrogenated ergot alkaloid, dihydroergocristine, which is employed in the management of organic brain syndrome. In vitro and in vivo experimental studies have shown that dihydroergocristine has α 1 -antagonist activity and is able to stimulate dopaminergic receptors. 16, 17 There are also studies that support the effectiveness of aniracetam 18, 19 and piracetam. 20 The aim of this study is to determine retrospectively whether or not any difference in efficacy exists between AChE-Is and nootropics. Differences in the side-effect profile were not investigated in this study.
Patients and methods

STUDY DESIGN
This retrospective study was based on data from elderly people who were examined at the Memory and Dementia Outpatient Clinic of the 'G. Papanikolaou' General Hospital between 1991 and 1999. The study comprised, from September 1991 to September 1996, patients who had been receiving nootropics (piracetam, aniracetam, nimodopine and dihydroergocristine), and from September 1996 to December 1999, patients who were receiving AChE-Is (tacrine and donepezil).
In order to compare the efficacy of the two treatment groups over the same duration of treatment, it was necessary to limit this study to the period of approximately 2 years because the administration of AChE-Is began in Greece in 1996. 
INCLUSION CRITERIA
ASSESSMENT OF EFFICACY
In order to evaluate the efficacy of treatment over time, we used data gathered at 6-monthly intervals for a minimum of 2 years on the following tests: the Mini-Mental State Examination (MMSE); 21, 22 the Cambridge Cognitive Examination for the Elderly (CAMCOG); 23, 24 and the Functional Rating Scale for Symptoms of Dementia (FRSSD). 25 In order to exclude depression as a factor, we also investigated the mean change in score on the Geriatric Depression Scale (GDS), short form, for both treatment groups. 26 Patients who had a GDS score above 5 were considered to be depressed and were treated for their depression first.
To determine whether or not the severity of disease has any impact on efficacy, the patients from both treatment groups were categorized into one of three groups according to their MMSE scores at baseline evaluation. These categories were: mild dementia (MMSE score between 21 and 26); moderate dementia (MMSE score between 11 and 20); and severe dementia (MMSE score between 0 and 10).
STATISTICAL ANALYSIS
Student's t-test and Pearson's χ 2 -test were used to compare the demographic variables for both treatment groups. Student's t-test was also performed between mean values (total scores as well as change over time) for both groups at each time-point.
In addition, Student's t-test was used to investigate whether or not efficacy of treatment depended on gender of the patient.
Results
DEMOGRAPHICAL VARIABLES
The study comprised, from September 1991 to September 1996, 281 patients who had been receiving nootropics (piracetam, aniracetam, nimodopine and dihydroergocristine), and from September 1996 to December 1999, 229 patients who were receiving AChE-Is (tacrine and donepezil). The two treatment groups were comparable with regard to age, education (measured in years of education) and the proportion of males to females (Tables 1  and 2 ). 
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No significant differences were shown in mean change in score between the two treatment groups (Table 3 ). This was also true in patients with severe dementia ( (Table 5 ).
In patients with mild dementia, there was a significantly greater decrease in MMSE score in the nootropics group compared with the AChE-Is group at each time-point (P < 0.05 at 6, 12 and 18 months and P < 0.001 at 24+ months) ( Table 6 ).
Comparison of the data for males and females showed that there was a significantly greater increase in MMSE and CAMCOG scores in the AChE-Is group in men compared with women for the 6-month period. In addition, for the 24+-month period, a significantly greater decrease in MMSE score was seen in the nootropics group in men compared with women (Tables 7 and   8 ).
Discussion
In this retrospective study of data collected from two time-periods, nootropics appear to have a comparable efficacy to AChE-Is in AD. This is especially apparent in moderate and severe dementia.
One explanation may be the side-effects of AChE-Is, or it could be that nootropics have a neuroprotective activity for any kind of neurogeneration.
Another possible explanation is that some 
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patients with AD respond dramatically while others deteriorate with no obvious explanation. There are also other types of dementia which do not begin with memory disorder, but with other symptoms such as early aphasia, a schizophrenia-like psychosis, 27 or a progressive visuospatial disorder. 28 AD is a heterogeneous diseaseclinically, genetically, pathologically and biochemically. 29, 30 It may be caused by a large number of underlying factors; alternatively, it may be a spectrum of different diseases of similar pathology and clinical features.
The variability in clinical presentation, rate of disease progression and performance on psychometric tests means that it is difficult to demonstrate significant treatment effects. Not all patients would be expected to respond to a single treatment, and the degree of benefit may vary depending on genetic factors as well as on underlying neuroanatomical, biochemical and neurotransmitter pathologies and severity of illness. If the underlying processes differ significantly from one individual to another, a single biochemical approach to treatment will not necessarily work in all patients. The course of AD may be dependent on the interplay of the patients' genetic makeup and environmental factors. The role of environmental factors in AD, however, has yet to be elucidated.
Another possible theory is tolerance. Is it the same phenomenon as with L-dopamine in Parkinson's disease? From these results, it appears that after the 6-month period, patients with either mild or moderate AD might be expected to respond better to AChE-Is than to nootropics. In particular, in patients with mild AD, the difference in mean change in the psychiatric tests between the two treatment groups increased from the 6-to 24+-month time-point.
It is not yet known how to determine which type of medication patients with AD will respond to best. The use of both drugs at least for 6 months at the beginning of the dementia may help us to decide which drug is likely to be more efficacious. Based on a worsening of 3 points per year on the MMSE in untreated patients, a recognizable treatment effect (i.e. a 1.5-point difference between treatment groups) would not be apparent until a patient had been treated for 6 months. In addition, the effect would be judged as clinically important only if it was also recognizable on a clinician-rated global assessment.
The second lesson learned is that whether we use drugs without any significant sideeffects or drugs which are effective compared with placebo but with side-effects, we have the same results after a period of 2 years.
Interestingly, the results of this study suggest that men may respond to AChE-Is better than women. This is the first time this has been reported, and the finding is likely be very important for the pathogenesis of AD.
In conclusion, this study suggests that, until new, improved drugs with better efficacy and less side-effects reach the market, for best results it may be advisable to try a combination of nootropics and
